Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
9Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Petros Pharmaceuticals, Inc. (PTPI) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
2Distinct source URLs
8High confidence
0.805Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Petros Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
VIVUS-INC
VIVUS-INC
92%
Metuchen granted to Vivus a continuing security interest in all of its Stendra® API and products and its rights under the License Agreement
Petros Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
POS-T-VAC-LLC
POS-T-VAC-LLC
90%
Petros also historically marketed its own line of ED products in the form of vacuum erection device products through its previous subsidiaries, Timm Medical and PTV
TIMM-MEDICAL-TECHNOLOGIES-INC
TIMM-MEDICAL-TECHNOLOGIES-INC
90%
Petros also historically marketed its own line of ED products in the form of vacuum erection device products through its previous subsidiaries, Timm Medical and PTV
VIVUS-INC
VIVUS-INC
90%
Metuchen agreed to transfer all completed inventory of Stendra® and all substantially manufactured inventory of Stendra® on hand to Vivus at Metuchen’s sole expense
METUCHEN
METUCHEN
85%
Petros has an established industry-wide network of prospective companies that may license our technology, if it is successfully developed, which the Company expects will serve as its primary target c…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from PTPI graph: s by engaging business development contractors to further the Company’s goals and objectives. 2 Table of Contents Wh…
SNYNF
Sanofi
72%
s by engaging business development contractors to further the Company’s goals and objectives. 2 Table of Contents While the Company’s intended primary business model is based in developing and licens…
METUCHEN-NEUROTROPE-TIMM-MEDICAL-TECHNOLOGIES-IN
METUCHEN-NEUROTROPE-TIMM-MEDICAL-TECHNOLOGIES-IN
62%
dentify risks from cybersecurity threats, including the threat of a cybersecurity incident, and manage our risk assessment program. Among other things, these providers advise on best practices for sa…
METUCHEN-PHARMACEUTICALS-LLC
METUCHEN-PHARMACEUTICALS-LLC
62%
dentify risks from cybersecurity threats, including the threat of a cybersecurity incident, and manage our risk assessment program. Among other things, these providers advise on best practices for sa…
PETROS-NEUROTROPE-INC
PETROS-NEUROTROPE-INC
62%
dentify risks from cybersecurity threats, including the threat of a cybersecurity incident, and manage our risk assessment program. Among other things, these providers advise on best practices for sa…
Petros Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
PTPI-DEBT-11947
Warrants outstanding: 0.27
90%
xbrl warrant detail from xbrl 2026-03-31.
PTPI-DEBT
Debt stack $1.7M
90%
Market cache reports total debt of $1.7M.
PTPI-DEBT-11948
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
Petros Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Petros Pharmaceuticals, Inc..
Petros Pharmaceuticals, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Petros Pharmaceuticals, Inc..
Petros Pharmaceuticals, Inc. Extended Supply Chain Network
